Our COVID19 phase 2 clinical trial for our lead product, rhu-pGSN, has begun.

Share on facebook
Share on twitter
Share on linkedin

June 12, 2012: US Patent Granted for Plasma Gelsolin as a Diagnostic and Biomarker in Treatment of Inflammation

BioAegis’ Patent Rights Extend to Applications for Inflammation

Recombinant plasma gelsolin has been shown to be a biomarker of inflammation in a wide range of diseases and in particular in rheumatoid arthritis (RA). This abundant human plasma protein is expected to have utility in patients with RA, as well as other inflammatory diseases.